News Release

Pacemakers could protect patients with epilepsy from sudden unexplained death

NB. Please note that if you are outside North America, the embargo for LANCET press material is 0001 hours UK Time Friday 17 December 2004.

Peer-Reviewed Publication

The Lancet_DELETED

Results of a UK study in this week's issue of THE LANCET highlight how interruptions to the heart's rhythm is an under-reported consequence of epileptic seizures, and that the use of cardiac pacemakers by some epilepsy patients could play a future role in protecting against sudden unexplained death.

Patients with epilepsy are at risk of sudden unexplained death. Irregular heart rhythm as a result of neurological dysfunction during seizures is thought to be a possible cause.

John Duncan (Institute of Neurology UCL and National Society for Epilepsy, London) and colleagues studied 20 patients with epilepsy who received an implantable device which monitored heart rhythms. These devices were programmed to record automatically for very slow heart beat (bradycardia, 40 beats per minute or less) or very fast beats (tachycardia, 140 beats or more per minute) were detected.

Patients were studied for up to 22 months; ECG patterns monitored heart rhythms during 377 seizures. Heart rate during habitual seizures exceeded 100 beats per minute among 16 patients. Four patients had bradycardia or periods of asystole (cardiac inactivity) and were given permanent pacemaker insertion. Three of these four patients had potentially fatal asystole.

Professor Duncan comments: "We have shown that implantable loop recorders can identify potentially fatal cardiac abnormalities in patients with epilepsy, and suggest that the incidence of bradycardia and asystole has previously been under-reported. Asystole underlies a proportion of sudden unexpected deaths in epilepsy, which could be prevented by cardiac-pacemaker insertion."

In an accompanying commentary (p 2157), Lawrence J Hirsch and W Allen Houser (Mailman School of Public Health, Columbia University, New York City, USA) consider the present study an important step forward but caution that it is too early to change clinical practice until larger confirmatory studies are conclusive.

###

Contact: Professor John S Duncan, Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London WC1N 3BG, UK;
T) 44-207-837-3611;
j.duncan@ion.ucl.ac.uk

Dr W Allen Hauser, University College of Physicians and Surgeons, Columbia University, Sergievsky Center, 630 West 168th Street, New York NY 10032, USA;
T) 1-212-305-2447;
hausera@sergievsky.cpmc.columbia.edu


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.